Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
DFFN
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Relative Strength
DFFN
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
globenewswire.com
7 hours ago
prnewswire.com
13 hours ago
prnewswire.com
14 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
NASDAQ
0.41Ā ( 10.28%)
After-hours NaN$0.00 (0.00%)
Relative Strenght
Volume Buzz
631%
Earning Acce
No
Dist 52w H.
69%Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-2.22
vsĀ -2.22
Q2.23
N/A
-1.04
vsĀ -2.06
Q3.23
+142%
0.57
vsĀ -1.37
Q4.23
N/A
NA
vsĀ NA
Q1.24
N/A
NA
vsĀ NA
Q2.24
+100%
NA
vsĀ -1.04
Q3.24
N/A
NA
vsĀ 0.57
Q4.24
N/A
NA
vsĀ NA
Q1.25
N/A
NA
vsĀ NA
Q2.25
N/A
NA
vsĀ NA
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NAĀ vsĀ NA
Q2.23
NA
NAĀ vsĀ NA
Q3.23
NA
NAĀ vsĀ NA
Q4.23
NA
NAĀ vsĀ NA
Q1.24
NA
NAĀ vsĀ NA
Q2.24
NA
NAĀ vsĀ NA
Q3.24
NA
NAĀ vsĀ NA
Q4.24
NA
NAĀ vsĀ NA
Q1.25
NA
NAĀ vsĀ NA
Q2.25
NA
NAĀ vsĀ NA
Return on Equity
QoQ
Q1.23
-25%
-0.25
vsĀ -0.20
Q2.23
-15%
-0.15
vsĀ -0.25
Q3.23
+22%
0.22
vsĀ -0.15
Q4.23
-32%
-0.32
vsĀ 0.22
Q1.24
-47%
-0.47
vsĀ -0.32
Q2.24
-5%
-0.05
vsĀ -0.47
Q3.24
-10%
-0.10
vsĀ -0.05
Q4.24
-17%
-0.17
vsĀ -0.10
Q1.25
-14%
-0.14
vsĀ -0.17
Q2.25
-19%
-0.19
vsĀ -0.14
Institutionnal Ownership
QoQ
Q4.19
15
15
vsĀ 11
36%
Q1.20
13
13
vsĀ 15
-13%
Q2.20
22
22
vsĀ 13
69%
Q3.20
22
22
vsĀ 22
NA
Q4.20
21
21
vsĀ 22
-5%
Q1.21
21
21
vsĀ 21
NA
Q2.21
22
22
vsĀ 21
5%
Q3.21
22
22
vsĀ 22
NA
Q4.21
18
18
vsĀ 22
-18%
Q1.22
18
18
vsĀ 18
NA
Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
H.C. Wainwright
upgradePrevious: Not converted
2022-08-16
Now: Buy
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How DFFN compares to sector?
